| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Mariacristina Di Marco, Riccardo Carloni, Stefania De Lorenzo, Cristina Mosconi, Andrea Palloni, Elisa Grassi, Daria Maria Filippini, Angela Dalia Ricci, Alessandro Rizzo, Alessandro Di Federico, Donatella Santini, Daniela Turchetti, Claudio Ricci, Carlo Ingaldi, Laura Alberici, Francesco Minni, Rita Golfieri, Giovanni Brandi and Riccardo Casadei |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Riccardo Carloni, MD, Doctor, Department of Experimental, Diagnostic, and Specialty Medicine - DIMES, Sant'Orsola-Malpighi Hospital, University of Bologna, Via Massarenti 9, Bologna 40138, Italy. riccardo.carloni2@studio.unibo.it |
| Key Words |
Mucinous cystadenocarcinoma; Pancreatic cancer; BRCA1 gene; Olaparib; Case report; |
| Core Tip |
Pancreatic mucinous cystadenocarcinoma (MCAC) is a rare malignancy with a poor prognosis when it presents metastases at diagnosis. Due to its very low incidence, there are no clear recommendations for treatment of advanced disease. Olaparib (oral PARP inhibitor) has remarkable curative effects on BRCA mutated pancreatic ductal adenocarcinoma, breast and ovarian cancers. Still, there are few data about its efficacy in the treatment of other types of pancreatic malignancies. Herein, we report the first case of a germline BRCA1 mutated MCAC patient effectively treated with olaparib, and we provide a brief overview of the most relevant clinical features of MCAC. |
| Publish Date |
2020-12-10 10:17 |
| Citation |
Di Marco M, Carloni R, De Lorenzo S, Mosconi C, Palloni A, Grassi E, Filippini DM, Ricci AD, Rizzo A, Di Federico A, Santini D, Turchetti D, Ricci C, Ingaldi C, Alberici L, Minni F, Golfieri R, Brandi G, Casadei R. Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report. World J Gastrointest Oncol 2020; 12(12): 1456-1463 |
| URL |
https://www.wjgnet.com/1948-5204/full/v12/i12/1456.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v12.i12.1456 |
